Join Dr. Paul Richardson and moderator Dr. Caron Jacobson for an in-depth look at the investigational cereblon E3 ligase modulator drugs (CELMoDs) iberdomide and mezigdomide, as well as novel oral protein degraders for treatment of patients with multiple myeloma. This session highlights their mechanisms of action and unique properties and the cutting-edge clinical trial data supporting their use in combination with current regimens. Participants will gain clear, evidence-based insights into how these emerging therapies fit can into the management landscape for both newly diagnosed and relapsed/refractory patients, as well as patient subgroups.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
100% of listed courses are free
36 of 36 courses listed here are free.
Collected from the provider’s public pages · source
Top 6 courses
-
-
-
-
-
-
Reflux Red Flags, and the Referral Riddle
0.25 Credits
Specialties served/covered
- Advanced Heart Failure & Transplant Cardiology
- Allergy & Clinical Immunology
- Cardiovascular Disease
- Dermatology
- Emergency Medicine
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- General & Adult Psychiatry
- General Pediatrics
- Hematology
- Interventional Cardiology
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Neurology
- Ophthalmology
- Pulmonary Disease
- Rheumatology
- Surgical Oncology
- Cardio-Vascular
- Emergency & Critical Care
- GI & Liver
- Medical Subspecialties
- Neurology
- Oncology & Hematology
- Pediatrics
- Primary care
- Psychiatry
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 1.25 credits
- Commercial Support
-
ReleasedJul 27, 2026
-
Last day to claim creditJul 28, 2027 10 months left
-
M3 IME B.V +1 Future Directions in Multiple Myeloma. The Impact of CELMoDs, MRD as a Clinical Endpoint, and the Importance of Shared Decision-Making
-
Research to Practice Inside the Issue: The Emerging Role of Cereblon E3 Ligase Modulators in Multiple Myeloma | 2026 (Webinar Video Proceedings)
-
Medical Learning Institute, Inc. A Community-Centered Approach to CELMoD Education in Relapsed/Refractory Multiple Myeloma
-
National Association for Continuing Education Trial Talk: Recent Research into Biologics in Asthma
-
National Association for Continuing Education Integrating TROP2-Directed ADCs into TNBC Treatment Plans: Novel Aspects of Efficacy and Safety Profiles
-
National Association for Continuing Education Responding to the Science Biologics in Practice in COPD
